How the US's 'America First' Bilateral MOUs Rewrite the Rules of Global Health Governance

For more than six decades, the architecture of United States global health assistance was defined by a multilateral, agency-driven approach. Through the US Agency for International Development (USAID) and the President’s Emergency Plan for AIDS Relief (PEPFAR), the federal government deployed billions of dollars annually via a vast network of non-governmental organizations, contractors, and multilateral institutions.[2]

That era has definitively ended. Following the dissolution of USAID in July 2025 and the formal US withdrawal from the World Health Organization in early 2026, the State Department has fully implemented the "America First Global Health Strategy."[2][3]

This new framework dismantles the traditional donor-recipient dynamic, replacing it with a series of strict, five-year bilateral Memoranda of Understanding (MOUs) negotiated directly with individual nations. As of August 2026, the US has signed 34 of these bilateral agreements, governing more than $24 billion in health spending through 2030.[1][3]

The shift is not merely administrative; it represents a fundamental philosophical reorientation of how global health is funded, governed, and executed. Under the legacy model, US funds flowed primarily to implementing partners—NGOs, universities, and health contractors—who managed clinics, distributed antiretroviral drugs, and trained local staff.[2][5]

The new MOUs mandate a rapid transition to direct government-to-government budget transfers and commodity provisions, cutting out the intermediary network entirely. The stated goal of this transition—framed in official documents as "self-reliance"—is to eliminate duplicative administrative overhead and force a faster transition to national ownership.[5][6]

By routing resources directly into the national warehouses and health ministries of partner countries, the strategy's architects argue that every taxpayer dollar is maximized for frontline impact rather than sustaining a permanent international aid industry.[6]

While the State Department markets the MOUs as a tool for sovereign empowerment, the actual mechanics introduce unprecedented financial expectations for recipient nations. Central to every new MOU is a strict co-investment mandate.[1][3]

Partner countries are no longer passive recipients of aid; they are contractually obligated to fund a significant, escalating share of their own health programs over the five-year lifespan of the agreement. Across the 34 signed agreements, recipient governments have pledged an average co-investment share of 39 percent.[1]

The burden varies dramatically by country. While the average sits near 40 percent, specific agreements demand far more aggressive domestic mobilization. Nigeria, for example, has committed to funding 59 percent of its MOU targets, while Botswana faces a staggering 78 percent co-investment mandate.[3]

Health economists and policy analysts warn that these aggressive benchmarks create severe vulnerabilities. If a partner nation experiences an economic downturn, a debt crisis, or a sudden revenue shortfall, it may default on its co-investment obligations, triggering conditionality clauses that allow the US to withhold its matching funds.[2][3]

Beyond the financial restructuring, the bilateral MOUs introduce stringent new security and data-sharing mandates that bypass established multilateral frameworks. The most consequential of these is the requirement for rapid pathogen intelligence sharing.[4][5]

Under the new agreements, partner nations must commit to detecting infectious disease outbreaks with pandemic potential within seven days of emergence. More critically, they are required to share biological specimens and genetic sequence data directly with the US government within five days of detection.[4]

This bilateral data pipeline effectively circumvents the World Health Organization’s Pathogen Access and Benefit Sharing (PABS) system. Developing nations have long argued that if they share viral samples, they must be guaranteed equitable access to the vaccines and therapeutics derived from them—a principle the WHO system attempts to formalize.[4]

By securing pathogen data through bilateral contracts rather than multilateral treaties, the US ensures its own domestic biosecurity and pharmaceutical development pipelines are protected, regardless of the broader international consensus. Critics argue this leverages essential health funding to extract highly sensitive sovereign health data.[4][5]

The implementation of this massive structural shift has not matched the streamlined rhetoric. The sudden transfer of authority from USAID’s specialized, field-based workforce to the State Department’s diplomatic corps caused significant friction in early 2026. During the initial transition period, spending on critical HIV-related activities temporarily plummeted by 34 percent as old contracts were terminated before new government-to-government pipelines were fully operational.[2]

As the 2026-2030 implementation window opens, the global health community is watching closely. The America First Global Health Strategy has successfully rewritten the rules of international assistance, prioritizing bilateral leverage, strict financial conditionality, and domestic security over the traditional ethos of unconditional humanitarian aid.[5][6]